IP Library Granted Patent US 9,046,403
Granted Patent B2
US 9,046,403 · App. 13/015,480 · Granted Jun 2, 2015

Systems and methods for managing use of a medicament

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,046,403
App. No.
13/015,480
Granted
Jun 2, 2015
Kind
B2
Abstract

Systems and methods for managing use of a pharmaceutical product are provided. The systems and methods utilize an external cover and a container, along with a first material and a pharmaceutical product that are each contained within an internal space that exists when the external cover is in a closed position relative to the container. Release of the first material may bond the external cover to the container, may result in the first material coming into contact with the pharmaceutical product, or both.

Claims (31)

1. A pharmaceutical product supply, comprising:

a container comprising a sidewall, an end wall, and an open end, wherein said end wall and said open end are oppositely disposed, wherein a boundary of a first space is defined by said sidewall and said end wall, and wherein said open end leads into said first space;

an external cover comprising a receptacle, an outlet port from said receptacle, and a seal blocking said outlet port;

pharmaceutical product disposed within said first space of said container, wherein said external cover blocks said open end and encloses said pharmaceutical product within said container when said external cover is detachably engaged with said container;

a first material within said receptacle of said external cover;

a release mechanism, wherein activation of said release mechanism is independent of movement of said external cover relative to said container;

a first configuration where said receptacle of said external cover is isolated from said pharmaceutical product within said first space of said container such that said first material is also isolated from said pharmaceutical product within said first space of said container and such that said first material is confined within said receptacle, wherein said pharmaceutical product supply is in said first configuration prior to said activation of said release mechanism; and

a second configuration where said receptacle of said external cover is interconnected said first space of said container such that there is a passage from said receptacle, through said outlet port, though said open end, and into said first space, and such that said first material is released from said receptacle of said external cover, passes through said outlet port, passes through said open end of said container, and comes into contact with said pharmaceutical product within said first space of said container, wherein said second configuration is achieved by said activation of said release mechanism to disable said seal.

2. The pharmaceutical product supply of claim 1 , wherein said release mechanism is activatable to release said first material from a confined condition.

3. The pharmaceutical product supply of claim 1 , further comprising:

a containment disposed within said receptacle, wherein said first material is disposed within said containment.

4. The pharmaceutical product supply of claim 3 , wherein said containment is at a pressure greater than a pressure in a portion of said first space containing said pharmaceutical product.

5. The pharmaceutical product supply of claim 1 , wherein said first material is selected from the group consisting of an emetic, a taste deterrent, an adhesive, an epoxy, an olfactory repellent, a drug antagonist, or any combination thereof.

6. The pharmaceutical product supply of claim 1 , wherein said release mechanism is responsive to a signal to dispose said first material in a released state.

7. The pharmaceutical product supply of claim 1 , wherein said release mechanism is activatable in response to a timer.

8. The pharmaceutical product supply of claim 1 , wherein said release mechanism is manually activatable on an exterior of said pharmaceutical product supply.

9. The pharmaceutical product supply of claim 8 , wherein said release mechanism is accessible through an external cap.

10. The pharmaceutical product supply of claim 1 , wherein said release mechanism is activatable in response to a predetermined event, wherein said predetermined event comprises at least one of:

exceeding a predetermined number of detachments of said external cover from said container over a predetermined time period; and

a predetermined time period elapsing without an occurrence of a predetermined number of detachments of said external cover from said container.

11. The pharmaceutical product supply of claim 1 , further comprising:

a sensor operative to determine if said external cover is engaged with said container, wherein said release mechanism is activatable when said external cover is engaged with said container and is not activatable when said external cover is not engaged with said container.

12. The pharmaceutical product supply of claim 1 , further comprising:

an alert indicative of a remaining time period prior to activation of said release mechanism.

13. A pharmaceutical product supply system, comprising:

the pharmaceutical product supply of claim 1 ; and

a remotely located trigger, wherein said release mechanism is activatable in response to said remotely located trigger.

14. A pharmaceutical product supply system, comprising:

the pharmaceutical product supply of claim 1 ; and

a plurality of selectable external covers that are detachably engageable with said container, wherein a first group of said plurality of selectable external covers is associated with a first timed release of said first material, wherein a second group of said plurality of external covers is associated with a second timed release of said first material that is different from said first timed release, and wherein said external cover is selected from said plurality of selectable external covers.

15. The pharmaceutical product supply system of claim 14 , wherein said first group of said plurality of selectable external covers bear corresponding first indicia indicative of said first timed release and said second group of said plurality of selectable external covers bear corresponding second indicia indicative of said second timed release.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Dec 14, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC.
Reel/Frame 027380/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2011
From: ORTENZI, VERNON D.; ZIEMBA, ROBERT J.; KARGER, SIMON A.; CRAFT, BRANDON; DATTA, PARIKKHIT; MAWBY, ANDREW; BICKERSTAFFE, JEREMY
To: MALLINCKRODT INC.
Reel/Frame 026410/0940 →